Skip to main content

Find Clinical Trials

Home
Conditions
QL1706

Clinical trial condition

QL1706

Explore clinical trials studying QL1706. Study availability and eligibility vary by location and protocol.

4 public trials 1 recruiting study

Refine in advanced search Browse all conditions

QL1706 trial results

Recruiting

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

NCT07327788

Conditions: Bevacizumab, Hepatecellular Carcinoma, Iparomlimab and Tuvonralimab Injection, +3 more
Locations: Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT07533305

Conditions: ESCC, First-line Therapy, QL1706
Locations: Not specified

View Trial Details

Not Yet Recruiting

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

NCT07372079

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations: Tianjin Medical University Cancer Institute & Hospital Tianjin, China

View Trial Details

Not Yet Recruiting

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

NCT07156682

Conditions: Colon Cancer, Colonic Diseases, Colonic Neoplasms, +11 more
Locations: Qilu hospital of Shandong University Jinan, Shandong, China

View Trial Details